Multiparametric magnetic resonance imaging in the management and diagnosis of prostate cancer: Current applications and strategies

Current Urology Reports

Volumn 15, Issue 3, 2014, Pages

  Lee, Daniel J ^a   Ahmed, Hashim U ^b,c   Moore, Caroline M ^b,c   Emberton, Mark ^b,c   Ehdaie, Behfar ^d  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Active surveillance; Diagnosis; Management; Multiparametric magnetic resonance imaging; Prostate cancer; Prostate specific antigen (PSA)

Indexed keywords

BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CRYOTHERAPY; DIAGNOSTIC ACCURACY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TREATMENT PLANNING; BLOOD; DIFFUSION WEIGHTED IMAGING; IMAGE GUIDED BIOPSY; MALE; METHODOLOGY; PATHOLOGY; PROSTATE; PROSTATE TUMOR; WATCHFUL WAITING;

CONTRAST MEDIUM; DIAGNOSTIC AGENT; KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 3, HUMAN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROSTATE SPECIFIC ANTIGEN;

CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; IMAGE-GUIDED BIOPSY; KALLIKREINS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

EID: 84891894631     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-013-0390-1     Document Type: Review

References (107)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Shariat S, Kattan M, Vickers A, Karakiewicz P, Scardino P. Critical review of prostate cancer predictive tools. Future Oncol. 2009;5:1555-84.
3. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302:1202-9.
4. Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368:436-45. Important study highlighting the quality of life after radiation therapy and prostatectomy for PCa.
5. Andriole GL, Crawford ED, Grubb 3rd RL, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125-32.
6. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981-90.
7. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:762-71.
8. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;98:715-7. (Pubitemid 43821789)
9. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol. 2009;27:4300-5.
10. Briganti A, Larcher A, Abdollah F, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol. 2012;61:480-7.
11. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368-74. (Pubitemid 24037911)
12. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126-31. An important active surveillance cohort with mature data and long-term follow-up.
13. Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll PR. Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol. 2009;181:1628-33. discussion 33-4.
14. Cohen MS, Hanley RS, Kurteva T, et al. Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. Eur Urol. 2008;54:371-81.
15. Komai Y, Numao N, Yoshida S, et al. High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy. J Urol. 2013;190:867-73.
16. Ehdaie B, Vertosick E, Spaliviero M, et al. The Impact of Repeat Biopsies on Infectious Complications in Men with Prostate Cancer on Active Surveillance. J Urol. Sep 6.
17. Wagenlehner FM, van Oostrum E, Tenke P, et al. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol. Mar: 63:521-7.
18. Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2005;48:546-51. (Pubitemid 41278578)
19. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61-71.
20. Onik G. The male lumpectomy: rationale for a cancer targeted approach for prostate cryoablation. A review. Technol Cancer Res Treat. 2004;3:365-70. (Pubitemid 39096608)
21. Uchida T, Ohkusa H, Nagata Y, Hyodo T, Satoh T, Irie A. Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int. 2006;97:56-61.
22. Moore CM, Hoh IM, Bown SG, Emberton M. Does photodynamic therapy have the necessary attributes to become a future treatment for organ-confined prostate cancer? BJU Int. 2005;96:754-8. (Pubitemid 41391373)
23. Ikonen S, Karkkainen P, Kivisaari L, et al. Magnetic resonance imaging of clinically localized prostatic cancer. J Urol. 1998;159:915-9. (Pubitemid 28106556)
24. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology. 1999;213:473-80. (Pubitemid 29510595)
25. Hricak H, White S, Vigneron D, et al. Carcinoma of the prostate gland:MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils. Radiology. 1994;193:703-9. (Pubitemid 24366938)
26. Rifkin MD, Zerhouni EA, Gatsonis CA, et al. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med. 1990;323:621-6. (Pubitemid 20280191)
27. Carter HB, Brem RF, Tempany CM, et al. Nonpalpable prostate cancer: detection with MR imaging. Radiology. 1991;178:523-5.
28. Quinn SF, Franzini DA, Demlow TA, et al. MR imaging of prostate cancer with an endorectal surface coil technique: correlation with whole-mount specimens. Radiology. 1994;190:323-7. (Pubitemid 24044227)
29. Ellis JH, Tempany C, Sarin MS, Gatsonis C, Rifkin MD, McNeil BJ. MR imaging and sonography of early prostatic cancer: pathologic and imaging features that influence identification and diagnosis. AJR Am J Roentgenol. 1994;162:865-72. (Pubitemid 24115872)
30. Noguchi M, Stamey TA, Neal JE, Yemoto CE. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. J Urol. 2000;163:1751-5. (Pubitemid 30366728)
31. Al-Ahmadie HA, Tickoo SK, Olgac S, et al. Anterior-predominant prostatic tumors: zone of origin and pathologic outcomes at radical prostatectomy. Am J Surg Pathol. 2008;32:229-35. (Pubitemid 351172137)
32. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988;12:897-906. (Pubitemid 19011040)
33. Lawrentschuk N, Haider MA, Daljeet N, et al. Prostatic evasive anterior tumours': the role of magnetic resonance imaging. BJU Int. 2010;105:1231-6.
34. Lemaitre L, Puech P, Poncelet E, et al. Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. Eur Radiol. 2009;19:470-80.
35. Roethke MC, Lichy MP, Jurgschat L, et al. Tumorsize dependent detection rate of endorectal MRI of prostate cancer-a histopathologic correlation with whole-mount sections in 70 patients with prostate cancer. Eur J Radiol. 2011;79:189-95.
36. Jager GJ, Ruijter ET, van de Kaa CA, et al. Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology. 1997;203:645-52. (Pubitemid 27227409)
37. Haider MA, van der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol. 2007;189:323-8. (Pubitemid 47195916)
38. Turkbey B, Mani H, Shah V, et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol. 2011;186:1818-24.
39. Nagarajan R, Margolis D, Raman S, et al. Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer. Adv Urol. 2012;2012:374805.
40. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol. 1992;23:273-9.
41. Verma S, Rajesh A, Morales H, et al. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol. 2011;196:374-81.
42. Hambrock T, Somford DM, Huisman HJ, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology. 2011;259:453-61.
43. de Souza NM, Riches SF, Vanas NJ, et al. Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol. 2008;63:774-82.
44. Tamada T, Sone T, Jo Y, et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging. 2008;28:720-6.
45. Somford DM, Hambrock T, Hulsbergen-van de Kaa CA, et al. Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score
46. Kirkham AP, Haslam P, Keanie JY, et al. Prostate MRI: Who, when, and how? Report from a UK consensus meeting. Clin Radiol. 2013;68:1016-23.
47. Labanaris AP, Zugor V, Takriti S, et al. The role of conventional and functional endorectal magnetic resonance imaging in the decision of whether to preserve or resect the neurovascular bundles during radical retropubic prostatectomy. Scand J Urol Nephrol. 2009;43:25-31.
48. Westphalen AC, Coakley FV, Roach 3rd M, McCulloch CE, Kurhanewicz J. Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology. 2010;256:485-92.
49. van As NJ, Norman AR, Thomas K, et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol. 2008;54:1297-305.
50. Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007;178:2359-64. discussion 64-5.
51. Roemeling S, Roobol MJ, de Vries SH, et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol. 2007;51:1244-50. discussion 51.
52. Khatami A, Aus G, Damber JE, Lilja H, Lodding P, Hugosson J. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer. 2007;120:170-4.
53. Vargas HA, Akin O, Afaq A, et al. Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol. 2012;188:1732-8. The use of MRI imaging improved the prediction of the biopsy result, which could potentially be an important application in active surveillance.
54. Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol. 2003;170:1792-7. (Pubitemid 37254930)
55. Carter HB, Sauvageot J, Walsh PC, Epstein JI. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol. 1997;157:2206-9. (Pubitemid 27208672)
56. Kattan MW, Marasco J. What is a real nomogram? Semin Oncol. 2010;37:23-6.
57. Epstein JI, Sanderson H, Carter HB, Scharfstein DO. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology. 2005;66:356-60. (Pubitemid 41138097)
58. Wang L, Hricak H, Kattan MW, Chen HN, Scardino PT, Kuroiwa K. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology. 2006;238:597-603. (Pubitemid 43134372)
59. Wang L, Hricak H, Kattan MW, et al. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. Radiology. 2007;242:182-8. (Pubitemid 44956023)
60. Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology. 2011;261:46-66.
61. Shukla-Dave A, Hricak H, Kattan MW, et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int. 2007;99:786-93. (Pubitemid 46439567)
62. Shukla-Dave A, Hricak H, Akin O, et al. Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer. BJU Int. 2012;109:1315-22. A significant improvement was noted in the AUC in predicting high-risk disease after incorporating MRI to the preoperative nomograms.
63. Stamatakis L, Siddiqui MM, Nix JW, et al. Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer. 2013;119:3359-66.
64. Morgan VA, Riches SF, Thomas K, et al. Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance. Br J Radiol. 2011;84:31-7.
65. Stevens DM, Moore C, Ahmed H, et al. The natural history of untreated prostate MRI lesions in an active surveillance prostate cancer population: 260 patient years. Eur Urol. 1996;11 Suppl 2012:e1096-e196.
66. Robertson NL, Moore CM, Ambler G, et al. MAPPED study design: a 6 month randomised controlled study to evaluate the effect of dutasteride on prostate cancer volume using magnetic resonance imaging. Contemp Clin Trials. 2013;34:80-9.
67. Moore CM, Robertson NL, Arsanious N, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol. 2013;63:125-40.
68. Haffner J, Lemaitre L, Puech P, et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int. 2011;108:E171-8.
69. Park BK, Park JW, Park SY, et al. Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound-guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy. AJR Am J Roentgenol. 2011;197:W876-81.
70. Watanabe Y, Terai A, Araki T, et al. Detection and localization of prostate cancer with the targeted biopsy strategy based on ADC map: a prospective large-scale cohort study. J Magn Reson Imaging. 2012;35:1414-21. Large prospective trial of 1400 men to assess the cancer detection rate using ADC maps.
71. Moore CM, Kasivisvanathan V, Eggener S, et al. Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group. Eur Urol. 2013;64:544-52.
72. Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, et al. Prospective Assessment of Prostate Cancer Aggressiveness Using 3-T Diffusion-Weighted Magnetic Resonance Imaging-Guided Biopsies Versus a Systematic 10-Core Transrectal Ultrasound Prostate Biopsy Cohort. Eur Urol. 2012;61(1):177-84.
73. Siddiqui MM, Rais-Bahrami S, Truong H, et al. Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy Significantly Upgrades Prostate Cancer Versus Systematic 12-core Transrectal Ultrasound Biopsy. Eur Urol. 2013;64:713-9. Prospective trial of 580 patients that found increased detection of clinically significant PCa by utilizing MR-guided biopsies.
74. Arumainayagam N, Ahmed HU, Moore CM, et al. Multiparametric MR Imaging for Detection of Clinically Significant Prostate Cancer: A Validation Cohort Study with Transperineal Template Prostate Mapping as the Reference Standard. Radiology. 2013;268:761-9.
75. Hambrock T, Somford DM, Hoeks C, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol. 2010;183:520-7.
76. Sciarra A, Panebianco V, Ciccariello M, et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res. 2010;16:1875-83.
77. Prando A, Kurhanewicz J, Borges AP, Oliveira Jr EM, Figueiredo E. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patientswith elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology. 2005;236:903-10. (Pubitemid 41170854)
78. Busetto GM, De Berardinis E, Sciarra A, et al. Prostate Cancer Gene 3 and Multiparametric Magnetic Resonance Can Reduce Unnecessary Biopsies: Decision Curve Analysis to Evaluate Predictive Models. Urology. 2013;82(6):1355-62.
79. Sciarra A, Panebianco V, Cattarino S, et al. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy. BJU Int. 2012;110:1661-5.
80. Qayyum A, Coakley FV, Lu Y, et al. Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol. 2004;183:1079-83. (Pubitemid 44185100)
81. Tamada T, Sone T, Jo Y, et al. Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis. Radiology. 2008;248:531-9.
82. White S, Hricak H, Forstner R, et al. Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. Radiology. 1995;195:385-90.
83. Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol. 1999;17:1155.
84. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol. 2001;165:1146-51. (Pubitemid 32210224)
85. Sella T, Schwartz LH, Swindle PW, et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology. 2004;231:379-85. (Pubitemid 38552892)
86. Cirillo S, Petracchini M, Scotti L, et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrastenhanced imaging. Eur Radiol. 2009;19:761-9.
87. Casciani E, Polettini E, Carmenini E, et al. Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol. 2008;190:1187-92. (Pubitemid 351684918)
88. Crook J, Robertson S, Collin G, Zaleski V, Esche B. Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1993;27:31-7. (Pubitemid 23270654)
89. Kim CK, Park BK, Park W, Kim SS. Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience. Abdom Imaging. 2010;35:246-52.
90. Haider MA, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:425-30.
91. Kara T, Akata D, Akyol F. Karcaaltincaba M, Ozmen M. The value of dynamic contrast-enhanced MRI in the detection of recurrent prostate cancer after external beam radiotherapy: correlation with transrectal ultrasound and pathological findings. Diagn Interv Radiol. 2011;17:38-43.
92. Arumainayagam N, Kumaar S, Ahmed HU, et al. Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy. BJU Int. 2010;106:991-7.
93. De Visschere PJ, De Meerleer GO, Futterer JJ, Villeirs GM. Role of MRI in follow-up after focal therapy for prostate carcinoma. AJR Am J Roentgenol. 2010;194:1427-33.
94. Meiers I, Waters DJ, Bostwick DG. Preoperative prediction of multifocal prostate cancer and application of focal therapy: review 2007. Urology. 2007;70:3-8.
95. Rieke V, Kinsey AM, Ross AB, et al. Referenceless MR thermometry for monitoring thermal ablation in the prostate. IEEE Trans Med Imaging. 2007;26:813-21. (Pubitemid 46842916)
96. Acher P, Rhode K, Morris S, et al. Comparison of combined x-ray radiography and magnetic resonance (XMR) imaging-versus computed tomography-based dosimetry for the evaluation of permanent prostate brachytherapy implants. Int J Radiat Oncol Biol Phys. 2008;71:1518-25.
97. Barkati M, Van Dyk S, Foroudi F, Narayan K. The use of magnetic resonance imaging for image-guided brachytherapy. J Med Imaging Radiat Oncol. 2010;54:137-41.
98. Pauly KB, Diederich CJ, Rieke V, et al. Magnetic resonance-guided high-intensity ultrasound ablation of the prostate. Top Magn Reson Imaging. 2006;17:195-207. (Pubitemid 46586212)
99. Stafford RJ, Fuentes D, Elliott AA, Weinberg JS, Ahrar K. Laser-induced thermal therapy for tumor ablation. Crit Rev Biomed Eng. 2010;38:79-100.
100. Rosenkrantz AB, Scionti SM, Mendrinos S, Taneja SS. Role of MRI in minimally invasive focal ablative therapy for prostate cancer. AJR Am J Roentgenol. 2011;197:W90-6.
101. Vellet AD, Saliken J, Donnelly B, et al. Prostatic cryosurgery: use of MR imaging in evaluation of success and technical modifications. Radiology. 1997;203:653-9. (Pubitemid 27227410)
102. Cirillo S, Petracchini M, D'Urso L, et al. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound. BJU Int. 2008;102:452-8. (Pubitemid 352032839)
103. Ben Cheikh A, Girouin N, Ryon-Taponnier P, et al. [MR detection of local prostate cancer recurrence after transrectal high-intensity focused US treatment: preliminary results]. J Radiol. 2008;89:571-7.
104. Punwani S, Emberton M, Walkden M, et al. Prostatic cancer surveillance following whole-gland high-intensity focused ultrasound: comparison of MRI and prostate-specific antigen for detection of residual or recurrent disease. Br J Radiol. 2012;85:720-8.
105. Azzouzi AR, Barret E, Moore CM, et al. TOOKAD((R)) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int. 2013;112:766-74.
106. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22:746-57.
107. Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011;59:477-94.